Pharmaceutical Technology on MSN23h
Atsena’s ATSN-201 gains FDA fast track status for XLRS treatmentThe Phase I/II LIGHTHOUSE trial is assessing the safety and tolerability of the gene therapy in male subjects.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback